NGNE compared with STOK: revenue, margins and what each company keeps, and the suppliers and customers both name

NGNENeurogene Inc.

Mkt capRevenueRevenue

STOKStoke Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

NGNENeurogene Inc.

STOKStoke Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NGNE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.1%▼−2.05%×0.15

May 13 '26±15.1%▲+3.42%×0.23

Q1 FY26±21.7%▲+7.95%×0.37

Q3 FY25±20.1%▼−14.04%×0.70

STOK

0 of 4at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26±10.1%▼−0.23%×0.02

Q2 FY26±10.8%▲+7.14%×0.66

= impliedNGNE realized, solidSTOK realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

Q1 FY26

±14.5%

▲+0.30%

×0.02

Jan 12 '26±18.0%▼−10.44%×0.58

NGNENeurogene Inc.

26.72▼−3.01%· post 26.72· delayed

Mkt cap$621.3MRevenue$925,000Q2 FY24Revenue—

STOKStoke Therapeutics, Inc.

26.46▲+0.64%· post 26.46· delayed

After hoursNov 2 '26delayed

Mkt cap$1.7BRevenue$9MQ2 FY26Revenue$184MFY25

Compare

After hoursNov 2 '26delayed

NGNENeurogene Inc.

STOKStoke Therapeutics, Inc.

26.72▼−3.01%post 26.72delayed

Price

26.46▲+0.64%post 26.46delayed

$621.3M

Mkt cap

$1.7B

Q2 FY24$925,000

Revenue

$9MQ2 FY26

—

Revenue

$184MFY25

NGNE26.72▼−3.01%vsSTOK26.46▲+0.64%After hoursNov 2 '26delayed